A number of other medical therapies have demonstrated efficacy in patients with Cushing’s disease, which exert their effects by inhibiting cortisol production at the adrenal glands (adrenocortical steroidogenesis inhibitors), blocking cortisol action at peripheral tissues (glucocorticoid receptor antagonists), or inhibiting ACTH release from the pituitary adenoma (dopamine receptor agonists) [20]. Here, POMC is linked to pituitary gland adenoma.